Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.
Nakaya A, Shibayama H, Uoshima N, Yamamura R, Yoshioka S, Imada K, Shimura Y, Hotta M, Matsui T, Kosugi S, Hanamoto H, Uchiyama H, Yoshihara S, Fuchida SI, Onda Y, Tanaka Y, Ohta K, Matsuda M, Kanda J, Yoko A, Kiyota M, Kawata E, Takahashi R, Fukushima K, Tanaka H, Yagi H, Takakuwa T, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M. Nakaya A, et al. Among authors: hanamoto h. Leuk Res Rep. 2023 Nov 17;20:100395. doi: 10.1016/j.lrr.2023.100395. eCollection 2023. Leuk Res Rep. 2023. PMID: 38076634 Free PMC article.
Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, Serizawa K, Rai S, Morita Y, Hanamoto H, Tsubaki K, Nishio K, Matsumura I. Taniguchi Y, et al. Among authors: hanamoto h. Int J Hematol. 2017 Nov;106(5):691-703. doi: 10.1007/s12185-017-2302-5. Epub 2017 Aug 5. Int J Hematol. 2017. PMID: 28780601 Clinical Trial.
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura I, Matsuda M. Morita Y, et al. Among authors: hanamoto h. Cancer Sci. 2018 Oct;109(10):3209-3215. doi: 10.1111/cas.13739. Epub 2018 Aug 26. Cancer Sci. 2018. PMID: 30007103 Free PMC article. Clinical Trial.
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Takakuwa T, et al. Among authors: hanamoto h. Eur J Haematol. 2021 Apr;106(4):555-562. doi: 10.1111/ejh.13586. Epub 2021 Jan 31. Eur J Haematol. 2021. PMID: 33476404
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial.
Rai S, Inoue H, Hanamoto H, Matsuda M, Maeda Y, Wada Y, Haeno T, Watatani Y, Kumode T, Hirase C, Espinoza JL, Morita Y, Tanaka H, Tatsumi Y, Matsumura I. Rai S, et al. Among authors: hanamoto h. Int J Hematol. 2021 Aug;114(2):205-216. doi: 10.1007/s12185-021-03148-0. Epub 2021 Apr 17. Int J Hematol. 2021. PMID: 33864623
Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
Hotta M, Satake A, Yoshimura H, Fujita S, Katayama Y, Ota S, Hanamoto H, Oyake T, Ito S, Okada M, Nakanishi T, Ito T, Ishii K, Nomura S. Hotta M, et al. Among authors: hanamoto h. Transplant Cell Ther. 2021 Aug;27(8):660.e1-660.e8. doi: 10.1016/j.jtct.2021.04.025. Epub 2021 May 12. Transplant Cell Ther. 2021. PMID: 33989832 Free article.
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
Rai S, Inoue H, Sakai K, Hanamoto H, Matsuda M, Maeda Y, Haeno T, Watatani Y, Kumode T, Serizawa K, Taniguchi Y, Hirase C, Espinoza JL, Morita Y, Tanaka H, Ashida T, Tatsumi Y, Nishio K, Matsumura I. Rai S, et al. Among authors: hanamoto h. Cancer Sci. 2022 Feb;113(2):660-673. doi: 10.1111/cas.15224. Epub 2021 Dec 5. Cancer Sci. 2022. PMID: 34837284 Free PMC article.
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia.
Iida H, Imada K, Ueda Y, Kubo K, Yokota A, Ito Y, Kiguchi T, Hata T, Nawa Y, Ikezoe T, Uchida T, Morita Y, Kawashima I, Chiba M, Morimoto K, Hirooka S, Miyazaki Y, Ohno R, Naoe T; Study Group. Iida H, et al. Int J Hematol. 2022 May;115(5):694-703. doi: 10.1007/s12185-022-03307-x. Epub 2022 Feb 24. Int J Hematol. 2022. PMID: 35211840 Clinical Trial.
79 results